8-K: Travere Therapeutics Reports Strong Second Quarter 2024 Results Driven by FILSPARI Growth

Travere Therapeutics announced a successful second quarter of 2024, highlighted by significant growth in FILSPARI sales and patient start forms.

Summary

• Travere Therapeutics reported a total revenue of $54.1 million for the second quarter of 2024, which includes $52.2 million in net product sales.
• FILSPARI net product sales reached $27.1 million in the second quarter, a 37% increase compared to the previous quarter.
• The company received 521 new patient start forms (PSFs) for FILSPARI in the quarter, marking the sixth consecutive quarter of PSF growth, with a total of 2,484 PSFs received since launch.
• Research and development expenses were $54.3 million for the quarter, a decrease from $66.5 million in the same period of 2023.
• Selling, general, and administrative expenses were $64.8 million for the quarter, down from $68.2 million in the same period of 2023.
• The company's net loss for the quarter was $70.4 million, or $0.91 per basic share, compared to a net loss of $85.6 million, or $1.13 per basic share, for the same period in 2023.
• As of June 30, 2024, Travere had $325.4 million in cash, cash equivalents, and marketable securities.
• The company is awaiting a PDUFA target action date of September 5, 2024, for the full approval of FILSPARI in IgAN.
• The company expects a $17.5 million milestone payment from CSL Vifor upon conversion of the conditional marketing authorization to full approval in Europe.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong sales growth, increasing patient adoption, and progress towards full regulatory approval. While there is a net loss, the company's financial position is stable, and the overall tone is optimistic.

Positives

• FILSPARI sales are showing strong growth, with a 37% increase this quarter compared to the last.
• The number of new patient start forms for FILSPARI continues to increase, indicating growing adoption by physicians.
• The company is on track for potential full approval of FILSPARI in the U.S. in September.
• Travere has a strong cash position of $325.4 million.
• The company is making progress in expanding FILSPARI's availability globally, with launches expected in Europe and Japan.
• Research and development expenses have decreased, likely due to restructuring and the advancement of clinical programs.

Negatives

• The company reported a net loss of $70.4 million for the quarter.
• Total other expense, net, was $1.9 million, compared to total other income, net, of $2.1 million for the same period in 2023, primarily due to a non-cash charge related to the Renalys Pharma collaboration.

Risks

• The company faces risks associated with the regulatory review and approval process for FILSPARI.
• There is no guarantee that regulators will grant full approval of sparsentan for IgAN or FSGS.
• The company faces risks related to the timing and potential outcome of clinical studies.
• The company may need to raise additional funding to complete the development of its product candidates.
• The company faces risks associated with market acceptance of its commercial products, including efficacy, safety, price, reimbursement, and benefit over competing therapies.
• The company faces risks associated with global and macroeconomic conditions, including health epidemics and pandemics.

Future Outlook

The company anticipates full approval of FILSPARI in the U.S. by September 5, 2024, and expects to launch FILSPARI in Europe soon. Topline results for the pegtibatinase study are expected in 2026, and for the Renalys Pharma study in the second half of 2025. The company also plans to engage with regulators regarding a potential regulatory pathway for sparsentan in FSGS.

Management Comments

• Eric Dube, Ph.D., president and chief executive officer of Travere Therapeutics, stated that the second quarter represents the most successful quarter to date for the FILSPARI launch in the U.S.
• He also noted that the company achieved new highs in patient start forms and revenue due to more nephrologists adopting FILSPARI as the standard of care.
• He mentioned that the company is finalizing preparations for the full approval of FILSPARI in IgAN.

Industry Context

This announcement reflects the growing market for rare disease treatments, particularly in nephrology. The success of FILSPARI highlights the potential for targeted therapies in treating conditions like IgAN. The company's global expansion plans also align with the trend of pharmaceutical companies seeking to reach broader patient populations.

Comparison to Industry Standards

• The 37% quarter-over-quarter growth in FILSPARI sales is a strong performance compared to typical pharmaceutical product launches.
• The number of patient start forms received indicates a positive trend in physician adoption, which is a key metric for successful drug commercialization.
• The company's R&D spending is in line with other biopharmaceutical companies focused on clinical-stage development.
• The company's cash position is healthy, providing a buffer for ongoing operations and future investments.
• The company's progress in obtaining regulatory approvals in multiple regions is comparable to other companies in the rare disease space, such as Horizon Therapeutics and Alexion Pharmaceuticals.

Stakeholder Impact

• Shareholders will likely react positively to the strong sales growth and progress towards full approval of FILSPARI.
• Patients with IgAN will benefit from the increased availability of FILSPARI.
• Employees may be positively impacted by the company's growth and success.
• The company's partners, such as CSL Vifor and Renalys Pharma, will benefit from the continued development and commercialization of FILSPARI.

Next Steps

• The company will focus on the PDUFA target action date of September 5, 2024, for the full approval of FILSPARI in IgAN.
• The company will continue to work with its partner CSL Vifor to launch FILSPARI in Europe.
• The company will continue to advance the Phase 3 program for pegtibatinase.
• The company will engage with regulators to evaluate potential regulatory pathways for sparsentan in FSGS.

Key Dates

Keywords

FILSPARI, sparsentan, IgAN, FSGS, pegtibatinase, Travere Therapeutics, renal, kidney disease, PDUFA, clinical trial, biopharmaceutical, rare disease